Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2002, 48, 237-241

https://doi.org/10.14712/fb2002048060237

Rosiglitazone Improves Insulin Resistance, Lipid Profile and Promotes Adiposity in a Genetic Model of Metabolic Syndrome X

O. Šeda1,2, L. Kazdová1, D. Křenová2, Vladimír Křen2,3

1Institute for Clinical and Experimental Medicine, Prague, Czech Republic
2Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic
3Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic

Received September 2002
Accepted October 2002

RSG is a member of the TZD group of drugs widely used in treatment of type 2 diabetes. The underlying mechanism of TZD action in insulin-sensitive tissues is not fully understood. In this study we show that 14-day RSG administration in a new rodent model of metabolic syndrome X, polydactylous rat strain (PD/Cub), substantially improves its lipid profile (serum TGs 4.20 ± 0.23 vs 2.34 ± 0.14 mmol/l, P < 0.0001; FFA 0.46 ± 0.05 vs 0.33 ± 0.02 mmol/l, P = 0.017), diminishes the liver TG depots (15.76 ± 0.60 vs 8.44 ± 0.55 µmol/g, P < 0.0001), serum insulin concentrations (1.10 ± 0.08 vs 0.63 ± 0.02 nmol/l, P < 0.0001) and promotes visceral adiposity (adiposity index 1.28 ± 0.03 vs 1.85 ± 0.07, P < 0.0001). No changes were observed in serum or liver concentrations of cholesterol. Concomitantly, both basal and insulin-stimulated glycogen synthesis in red-fibre type muscle (m. soleus) was enhanced, as well as glucose uptake into adipose tissue. However, glucose oxidation in soleus (basal and insulin-stimulated) remained unchanged. In consent with previously published data we suggest the current pharmacogenetic study as a further proof of substantial influence of genetic background on the physiological outcome of TZD therapy.

Funding

This work was supported by following grants: GAUK 7/2000/C from the Grant Agency of Charles University, No. 303/01/1010 and No. 204/98/K015 from the Grant Agency of the Czech Republic, and No. 6367-3 from the Internal Grant Agency of the Ministry of Health of the Czech Republic.

References

26 live references